Low‐glycemic tumor microenvironments have been found to decreased T cell viability, which are associated with the low expression of zeste methyltransferase enhancer homolog 2 (EZH2) and decreased glycolytic function.27 The gene discussed is EZH2; the disease is neoplasm.